Greg Tampus, MD
Family Medicine · Lutherville Timonium, MDNPI 1356679138
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 94 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 22.6% — the pattern of someone who eats at a lot of different presentations.
Across 94 payments — averaging $35.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$757
- Otsuka America Pharmaceutical, Inc.$470
- Novartis$350
- Sunovion Pharmaceuticals Inc.$224
- Johnson & Johnson$215
- Avanir Pharmaceuticals, Inc.$200
- plus $1K from 20 others
Across 21 payments — averaging $34,864 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vertex$357K
- AstraZeneca$343K
- Teva Pharmaceuticals USA, Inc.$32K
What the payments were for
- Speaking & faculty fees$160%
- Food & beverage$3,334100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 17 | $757 |
| Otsuka America Pharmaceutical, Inc. | 10 | $470 |
| Novartis | 9 | $350 |
| Sunovion Pharmaceuticals Inc. | 9 | $224 |
| Johnson & Johnson | 3 | $215 |
| Avanir Pharmaceuticals, Inc. | 3 | $200 |
| Lilly USA, LLC | 7 | $144 |
| AbbVie | 1 | $123 |
| Smith+Nephew | 1 | $120 |
| Sumitomo Pharma America, Inc. | 4 | $80 |
| Lundbeck LLC | 3 | $76 |
| Merck | 4 | $72 |
| Urovant Sciences Inc | 1 | $69 |
| Collegium Pharmaceutical, Inc. | 3 | $65 |
| Boehringer Ingelheim | 3 | $60 |
| Scpharmaceuticals Inc. | 2 | $50 |
| Alkermes, Inc. | 2 | $47 |
| UCB, Inc. | 2 | $42 |
| Exact Sciences | 2 | $40 |
| Mylan Specialty L.p. | 1 | $27 |
| E.r. Squibb & Sons, L.L.C. | 2 | $27 |
| Amarin Pharma, Inc. | 1 | $21 |
| Amgen | 1 | $20 |
| Astellas Pharma US Inc | 1 | $19 |
| Acorda Therapeutics, Inc | 1 | $16 |
| Eisai Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,350 in reported general payments places this provider in the 85th percentile of 1,193 family medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 439 | $255,335 |
| JardianceEmpagliflozin | 172 | $111,496 |
| Plegridy PenPeginterferon Beta-1a | 21 | $95,758 |
| EntrestoSacubitril/Valsartan | 119 | $62,721 |
| GemtesaVibegron | 116 | $56,609 |
| XareltoRivaroxaban | 100 | $52,243 |
| JanuviaSitagliptin Phosphate | 89 | $51,408 |
| MyrbetriqMirabegron | 109 | $48,420 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 73 | $48,350 |
| CreonLipase/Protease/Amylase | 30 | $42,294 |
| RexultiBrexpiprazole | 32 | $36,981 |
| OzempicSemaglutide | 34 | $32,008 |
| Breo ElliptaFluticasone/Vilanterol | 60 | $25,038 |
| Atorvastatin Calcium | 1,567 | $21,144 |
| MounjaroTirzepatide | 20 | $19,814 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $60 | $132,530210 claims |
| NovartisEntresto | $350 | $62,721119 claims |
| AbbVieCreon, Linzess, Namzaric | $123 | $61,27762 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $80 | $56,609116 claims |
| Johnson & JohnsonXarelto | $215 | $52,243100 claims |
| MerckJanuvia | $72 | $51,40889 claims |
| Astellas Pharma US IncMyrbetriq | $19 | $48,420109 claims |
| Lilly USA, LLCMounjaro, Trulicity, Olanzapine | $144 | $41,713257 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $470 | $36,98132 claims |
| Novo NordiskOzempic | $757 | $32,00834 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,193 family medicine providers in Maryland.
Other family medicine in Lutherville Timonium
- Karen DonaldsonBaltimore$899K
- Louis JacquesBaltimore$522K
- Michael ObiefuneBaltimore$291K
- Thomas LawrenceBerlin$254K
- Casey ScottCambridge$88K
- Daljeet SalujaBaltimore$63K
- Sanjay SaxenaHagerstown$60K
- Cynthia KleppingerSilver Spring$51K
- Tramaine DavisBowie$43K
- Alkesh PatelColumbia$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.